Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Qicai Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1766-9395; OpenAlex author ID A5047546722, A5122073542. Sources: OpenAlex.

Their work

Papers
15 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 1 paper · 2021: 4 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 3 papers

Papers 15

  1. Prostaglandin E2-driven dedifferentiation of Schwann cells leads to perineural invasion in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41392-026-02648-x↗
  2. Alternative Splicing of Secretin Receptor (SCTR) and Its Low Expression Drive the Occurrence of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002569↗
  3. PIEZO1 enhances pancreatic cancer neurotropism. First author DOI 10.1186/s12935-026-04244-z↗
  4. Methylation of CALCA and CALCB in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1155/2021/2088345↗
  5. DDIT4 Novel Mutations in Pancreatic Cancer. Co-author DOI 10.1155/2021/6674404↗
  6. DDIT4 is involved in PPAR-γ mediated Fatty Acid intake to promote the Proliferation of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-157763/v1↗
  7. Pancreatic cancer: A review of epidemiology, trend, and risk factors. Co-author DOI 10.3748/wjg.v27.i27.4298↗
  8. PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.3892/ol.2019.11097↗
  9. The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China. Co-author DOI 10.1097/mpa.0000000000001222↗
  10. PRSS1 mutation: a possible pathomechanism of pancreatic carcinogenesis and pancreatic cancer. Co-author DOI 10.1186/s10020-019-0111-4↗
  11. Pancreatic cancer and associated exosomes. Last author DOI 10.3233/cbm-170258↗
  12. PRSS1 mutations and the proteinase/antiproteinase imbalance in the pathogenesis of pancreatic cancer. Co-author DOI 10.1007/s13277-015-3982-1↗
  13. Genetic instability in patients with pancreatic cancer analyzed by SCARs and electrochemical sensors. Co-author DOI 10.7754/clin.lab.2013.130225↗
  14. The -409 C/T genotype of PRSS1 protects against pancreatic cancer in the Han Chinese population. Co-author DOI 10.1007/s10620-011-1893-6↗
  15. Novel mutations of PRSS1 gene in patients with pancreatic cancer among Han population. First author PMID 22088471↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feng Gao · 9 shared papers, 2012–2026 · strength 1.30
  2. Ling Wang · 2 shared papers, 2026 · strength 0.59
  3. Shangeng Weng · 2 shared papers, 2026 · strength 0.59
  4. Fadian Ding · 4 shared papers, 2020–2021 · strength 0.51
  5. Yanqi Ke · 1 shared paper, 2026 · strength 0.43
  6. Feng Gao · 1 shared paper, 2026 · strength 0.43
  7. Youting Chen · 3 shared papers, 2020–2021 · strength 0.39
  8. Chengfei Zhao · 3 shared papers, 2017–2021 · strength 0.37
  9. Jinhong Li · 1 shared paper, 2026 · strength 0.32
  10. Xinhua Lin · 4 shared papers, 2011–2019 · strength 0.31
  11. Feng Gao · 2 shared papers, 2019–2021 · strength 0.27
  12. Jiahong Dong · 1 shared paper, 2026 · strength 0.27
  13. Jingwen Wang · 2 shared papers, 2019–2021 · strength 0.24
  14. Jian-Xiong Hu · 1 shared paper, 2021 · strength 0.15
  15. Shuyu Zhang · 1 shared paper, 2021 · strength 0.13
  16. Huasheng Wu · 1 shared paper, 2020 · strength 0.12
  17. Qingliang He · 1 shared paper, 2016 · strength 0.07
  18. Qiang Yi · 1 shared paper, 2016 · strength 0.07
  19. Chaoyang Wu · 1 shared paper, 2014 · strength 0.05
  20. Qingquan Chen · 1 shared paper, 2014 · strength 0.05
  21. Kai Zeng · 1 shared paper, 2011 · strength 0.03
  22. Qishui Ou · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.